serum amphiregulin in patients with advanced non-squamous, non-small cell lung cancer

Use of AREG as a biomarker in non-small cell lung cancershould be encouraged since AREG is correlated with a poor prognosis, resistance to treatments and to apoptosis.

lung tumor-associated dendritic cell-derived amphiregulin increased cancer progression.

Amphiregulin contained in non-small-cell lung carcinoma-derived exosomes induces osteoclast differentiation through the activation of EGFR pathway.

FOSL1 is a determinant of lung cancer in vivo and regulates tumor cell proliferation and survival, largely in the context of KRAS mutations through amphiregulin and cell survival gene regulation.

Results show that Areg is involved in the nuclear accumulation of IGF1R induced by gefitinib and preventing the induction of apoptosis of lung cancer cells.